Armor CAR T cells with enhanced potency for cancer immunotherapy

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Armor CAR T cells with enhanced potency for cancer immunotherapy

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

Discover how the differentiation status of nonactivated CAR T cells can improve therapeutic efficacy of cancer immunotherapy. In this webinar, the University of Pennsylvania’s Dr. Saba Ghassemi, will discuss strategies for enhanced CAR T cell persistence and function, for better, more durable anti-tumor responses. She will explore how metabolic engineering strategies and cytokine expression can enhance CAR T cell survival, persistence, and function in challenging conditions such as the tumor microenvironment.

Attend this webinar to learn about tools that provide deep insights into CAR T cell potency via real-time, label-free tracking of tumor killing. Additionally, discover how nonactivated CAR T cells can improve CAR T longevity and therapeutic efficacy.

Attend this webinar to learn about:

How real-time, label-free tracking with the Axion BioSystems Maestro Z enables continuous monitoring of tumor killing dynamics, allowing for the evaluation of different CAR T cell engineering strategies
The role of maintaining a stem-like phenotype in nonactivated CAR T cells can lead to enhanced persistence, metabolic fitness, and long-term effectiveness
Improving CAR T therapeutic efficacy through metabolic reprogramming strategies
Enhancing CAR T survival and function in the TME with cytokine expression and metabolic fitness optimization

Saba Ghassemi

Assistant Professor, Center for Cellular Immunotherapies at University of Pennsylvania

Dr. Saba Ghassemi is an Assistant Professor in the Department of Pathology and Laboratory Medicine and serves as a Principal Investigator at the Center for Cellular Immunotherapies at the University of Pennsylvania. Her research focuses on developing novel CAR T cells with enhanced potency through a multidisciplinary approach that integrates engineering with CAR T cell immunology.

Dr. Ghassemi pioneered the development of an abbreviated culture paradigm, resulting in less differentiated progeny with improved potency. This breakthrough led to a successful clinical trial at UPenn utilizing a 3-day manufacturing process. Additionally, she has devised a novel method for delivering CAR transgenes into quiescent T cells, enabling the generation of highly potent CAR T cells within 24 hours. Dr. Ghassemi is currently spearheading efforts to transition this innovative platform into an upcoming clinical trial at Penn.

Her groundbreaking work has garnered recognition through several research grants and patent applications aimed at enhancing CAR T cells' efficacy, expansion, and fitness for adoptive immunotherapy. Dr. Ghassemi's ongoing research endeavors focus on optimizing, streamlining, and automating the manufacturing process of CAR T cells, with the overarching goal of enhancing the translational applicability and accessibility of these novel therapies to a broader range of geographical locations and patient populations.